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Highlights 
1. CYP2C19 genotype only partially determines phenotypic appearance. 
2. CYP2C19*17 carriers have only the potential for increased gene expression. 
3. Consideration of non-genetic factors could improve the phenotype prediction. 
4. Co-medication and liver dysfunction are potential phenotype-modifying factors. 
 
Abstract 
Background: CYP2C19 is an important drug-metabolizing enzyme, responsible for 
metabolism of approximately 10% of the drugs on the market. Large inter-individual 
differences exist in metabolic activities, which are primarily attributed to genetic 
polymorphism of CYP2C19 gene. Conflicting results have been published about the role of 
CYP2C19 polymorphisms in metabolism of CYP2C19 substrates and clinical outcomes; thus, 
we aimed to investigate CYP2C19 genotype-phenotype associations, and we sought to elicit 
potential causes of discrepancies in the genotype-based prediction by incorporating the liver 
donors’ demographic data, drug administration events and pathological conditions. 
Methods: (S)-mephenytoin was used to assess CYP2C19 activities in human liver 
microsomes derived from 114 Hungarian organ donors. CYP2C19 genotype was determined 
by SNP genotyping for CYP2C19*2, CYP2C19*3, CYP2C19*4 and CYP2C19*17 variants, 
and CYP2C19 mRNA levels were measured by qPCR method. Clinical data of the donors 
were considered in the genotype-based phenotype prediction. 
Results: CYP2C19 phenotype of 40% of the donors was well-predicted from the genotype 
data, whereas the phenotype of 13% was underestimated displaying higher activity, and of 
47% was overestimated displaying lower activity than predicted from CYP2C19 genotype. 
Among the donors with overestimated phenotype, one was treated with CYP2C19 
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substrate/inhibitor, 9 were on amoxicillin-clavulanic acid therapy, 7 were chronic alcohol 
consumers and 9 had disease with inflammatory processes. 
Abbreviations: CAR, constitutive androstane receptor; CI, confidence interval; CYP, 
cytochrome P450; EM, extensive metabolizer; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; GR, glucocorticoid receptor; IM, intermediate metabolizer; PCR, polymerase 
chain reaction; PM, poor metabolizer; PXR, pregnane X receptor; SNP, single nucleotide 
polymorphism; UM, ultra-rapid metabolizer 
 
Conclusions: CYP2C19 genotype only partially determines the CYP2C19 phenotypic 
appearance; co-medication, diseases with inflammatory processes and aspecific factors, such 
as chronic alcohol consumption and amoxicillin-clavulanic acid therapy (or any drug therapy 
resulting in liver injury) seem to be potential phenotype-modifying factors. 
 
Abbreviations: CAR, constitutive androstane receptor; CI, confidence interval; CYP, 
cytochrome P450; EM, extensive metabolizer; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; GR, glucocorticoid receptor; IM, intermediate metabolizer; PCR, polymerase 
chain reaction; PM, poor metabolizer; PXR, pregnane X receptor; SNP, single nucleotide 
polymorphism; UM, ultra-rapid metabolizer 
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Introduction 
 CYP2C19 is a clinically important member of drug-metabolizing cytochrome P450 
(CYP) enzymes, and assuredly has critical role in several drug-drug interactions and adverse 
drug reactions [1]. Although CYP2C19 gives only a very small proportion of CYP content in 
human liver [2], it metabolizes about 10% of the drugs on the market, including proton pump 
inhibitors, antiplatelet drugs, antiepileptics, antidepressants and the antimalarial proguanil [3-
5]. The metabolism of these drugs is largely variable between individuals, which is primarily 
attributed to the polymorphisms of CYP2C19 gene. Populations are commonly divided into 
four phenotypic groups considering individuals’ CYP2C19 metabolic capacity, with sub-
populations of poor (PM), intermediate (IM), extensive (EM) and ultra-rapid (UM) 
metabolizers [6]. 
 CYP2C19 gene is highly polymorphic, hitherto 35 allelic variants have been identified 
(http://www.cypalleles.ki.se/cyp2c19.htm, the last update was on 2nd May 2017), many of 
them have significant effect on CYP2C19 enzyme activity. For instance, the CYP2C19*2 
variant commonly occurs in Caucasian populations (allele frequency: 12-18% [7, 8]), and 
profoundly affects CYP2C19 protein expression arising from a single nucleotide 
polymorphism (SNP) in exon 5 (19154G>A; rs4244285), which leads to aberrant mRNA 
splicing and undetectable protein level, whereas the rare CYP2C19*3 variant (allele frequency 
<1%) contains a SNP that creates a premature stop codon (17948G>A; rs4986893). 
CYP2C19*4 variant occurs rarely in the Caucasian population (allele frequency: <1%), and 
the allele carries GTG initial codon (1A>G; rs4986893), resulting in negligible protein 
expression and activity [3]. In contrast, the CYP2C19*17 allele is associated with elevated 
mRNA expression and protein level that supposedly causes ultra-rapid metabolism of 
CYP2C19 substrates. The CYP2C19*17 allele commonly occurs in Caucasians (allele 
frequency: 20-22%) and the variant carries a SNP in the promoter region of the gene 
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(−806C>T; rs12248560); however, the molecular mechanism that gives rise to increased gene 
expression is still unclear [5, 9]. Furthermore, the promoter region of the CYP2C19 gene 
consists of CAR/PXR (constitutive androstane receptor/pregnane X receptor) and GR 
(glucocorticoid receptor) binding sites; consequently, CYP2C19 gene expression is inducible 
by xenobiotics activating these nuclear receptors, such as phenobarbital, rifampicin and 
dexamethasone [9, 10]. 
 In general terms, subjects carrying two loss-of-function CYP2C19 alleles (e.g. 
CYP2C19*2, CYP2C19*3 or CYP2C19*4) are considered to be PMs with deficient enzyme 
activity. Individuals with single loss-of-function allele and a wild-type allele (CYP2C19*1) 
are IMs, whereas those with two wild-type alleles are EMs. Subjects homozygous or 
heterozygous for CYP2C19*17 allele are typically considered to be UMs, supposing loss-of-
function alleles are not present. Phenotypic classification of individuals carrying the 
CYP2C19*17 gain-of-function allele in combination with a loss-of-function allele is 
ambiguous; however, limited data suggest that CYP2C19*17 allele may not compensate for 
the loss-of-function allele; thus, such subjects mostly classified as IMs [11]. 
 Up to now, several investigations have been implemented to apply genotype-based 
therapies by utilizing CYP2C19 genetic data. A well-established example is the bioactivation 
of the antiplatelet clopidogrel by CYP2C19. A number of studies have demonstrated that 
CYP2C19*2 carriers are at increased risk for recurring cardiovascular events under 
clopidogrel therapy, comparing to those patients homozygous for the wild-type allele [4, 12]. 
In vivo clinical studies observed increases in drug area under the concentration-time curve of 
the proton-pump inhibitor omeprazole or lansoprazole in association with CYP2C19 genotype 
[13]. CYP2C19 genotype also has an effect on the pharmacokinetics of some antidepressants, 
such as citalopram [14] and amitriptyline [15]. On the other hand, a recent in vitro study using 
human liver microsomes reported that CYP2C19*1/*2 and CYP2C19*1/*3 genotypes have 
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almost no effect on CYP2C19 enzyme activity (omeprazole 5-hydroxylation) when compared 
with the homozygous wild-type genotype (CYP2C19*1/*1) [16]. Significant effect of the 
CYP2C19*17 variant on the therapy of CYP2C19 substrate citalopram and clopidogrel is not 
demonstrated unequivocally by in vivo trials [14, 17]. Although no statistically significant 
difference in CYP2C19 enzyme activity has been demonstrated between hepatic microsomes 
from subjects carrying heterozygous or homozygous CYP2C19*17 genotype 
(CYP2C19*1/*17 or CYP2C19*17/*17) and microsomes from those with homozygous wild-
type genotype, the subjects with CYP2C19*17/*17 and CYP2C19*1/*17 genotype exhibited 
modestly higher expression of CYP2C19 mRNA and protein [18, 19]. Additional 
contradictory results were published about the bioactivation of the antimalarial proguanil and 
chlorproguanil into their respective major active metabolite cycloguanil and chlorcycloguanil. 
CYP2C19 has been proposed to be the main enzyme catalysing cycloguanil formation by in 
vitro inhibition studies [20]. Moreover, relationship was found between CYP2C19 genotype 
and variation in proguanil and cycloguanil plasma concentrations in vivo; however, there was 
no association with clinical outcome [21]. 
 The present work attempted to clarify the conflicting literature of the CYP2C19 
phenotypic appearance. We used human liver microsomes and (S)-mephenytoin as probe 
substrate to characterize inter-individual variability of CYP2C19 enzyme activity, and aimed 
to delineate associations between the measured phenotype and the corresponding CYP2C19 
genotype. We also sought to elicit the potential causes of discrepancies in the genotype-based 
prediction by incorporating the donors’ demographic data, drug administration events as well 
as pathological conditions. 
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Materials and methods 
Human liver microsomes 
Human liver tissues (n=114) were obtained from organ transplant donors at the Department of 
Transplantation and Surgery, Semmelweis University (Budapest, Hungary) (Table 1). Human 
livers were perfused with Euro-Collin’s solution (Fresenius AG, Bad Homburg vdH, 
Germany) and excised. The tissues were homogenized in 0.1 M Tris-HCl buffer (pH 7.4) 
containing 1 mM EDTA and 154 mM KCl. Microsomes were prepared by differential 
centrifugation as described by van der Hoeven and Coon [22]. Microsomal protein content 
was determined by the method of Lowry et al. [23] with bovine serum albumin as the 
standard. Approximately 50 mg of liver tissues were homogenized in 1 ml of TRIzol reagent 
(Invitrogen, Carlsbad, CA), and the total RNA was extracted according to the manufacturer’s 
instructions. The RNA was precipitated by using ethanol and stored at -80°C for further 
analyses. 
CYP2C19 enzyme assay 
Published method was followed to determine mephenytoin 4’-hydroxylation selective for 
CYP2C19 [24]. The incubation mixture contained NADPH-generating system (1 mM NADP, 
10 mM glucose 6-phosphate, 5 mM MgCl2 and 2 units/ml glucose 6-phosphate 
dehydrogenase), human liver microsomes (1 mg/ml) and mephenytoin (1 mM). After 20-min 
incubation, the reaction was terminated by ice-cold methanol and the incubation mixture was 
centrifuged for 10 min at 10.000×g. High-performance liquid chromatographic analysis was 
performed according to published method [24]. CYP2C19 enzyme assay for each donor was 
performed in triplicate, and median (min, max) was calculated. 
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CYP2C19 genotyping 
Hydrolysis SNP analysis for CYP2C19*2, CYP2C19*3, CYP2C19*4 and CYP2C19*17 was 
performed by polymerase chain reaction (PCR) with TaqMan probes (Metabion, 
Planegg/Steinkirchen, Germany) using a CFX96 real-time detection system (Bio-Rad 
Laboratories). Primers and probes (Table 2) were designed based on the reference SNP 
sequences in the National Center for Biotechnology Information reference assembly. 
Genomic DNA was isolated from liver samples by Quick-DNA™ Universal Kit (Zymo 
Research, Irvine, CA). PCR was carried out with 30 ng of genomic DNA by using Luminaris 
Color Probe qPCR Master Mix (Thermo Fisher Scientific, Waltham, MA). To confirm the 
results of CYP2C19 genotyping, a sequence analysis was performed. The PCR products were 
sequenced directly in an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster 
City, CA) by the Sequencing Service of Biomi Ltd. (Gödöllő, Hungary). 
Analysis of CYP2C19 mRNA levels with quantitative real-time PCR 
Total RNA (3 µg) was reverse-transcribed into single-stranded cDNA by using iScript cDNA 
synthesis kit (Bio-Rad Laboratories, Hercules CA), and then real-time PCR with human 
cDNA was performed by using FastStart Taq DNA polymerase (LightCycler 480 Probes 
Master; Roche Diagnostics) and UPL probes for CYP2C19 (Roche Diagnostics). The 
sequences of primers and probe used for the real-time PCR analyses are shown in Table 2. 
The quantity of target RNA relative to that of the housekeeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was determined.  
Data analysis 
Hepatic CYP2C19 activities were determined individually in each donor, the frequency 
distribution of the CYP2C19 activities were recorded for 114 donors, and four categories 
(low, intermediate, high, ultra-high) were distinguished for poor, intermediate, extensive and 
ultra-rapid metabolizers. Approximately 10-15% of the donors displaying low CYP2C19 
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activity [<8 pmol/(mg protein*min)] were designated as phenotypic PMs, whereas 10-15% of 
the donors with ultra-high activities [>75 pmol/(mg protein*min)] were designated as 
phenotypic UMs. The donors displaying CYP2C19 activities between 8 and 75 
pmol/(mg protein*min) were considered to be phenotypic IMs and EMs. The cut-off value 
between IMs and EMs was the median of CYP2C19 activities [23 pmol/(mg protein*min)]. 
The donors’ CYP2C19 phenotypes were also predicted from their CYP2C19 genotypes, and 
the accuracy of prediction was evaluated on the basis of the activity-based CYP2C19 
categories. The donors carrying two loss-of-function alleles (CYP2C19*2, CYP2C19*3, 
CYP2C19*4) were considered to be PMs, those with one functional (CYP2C19*1) and one 
loss-of-function alleles were designated as IMs, the subjects with two functional alleles 
(CYP2C19*1/*1) were EMs, whereas the donors carrying the CYP2C19*17 allele (both 
homozygous and heterozygous) were UMs. Considering the ambiguous character of the 
CYP2C19*2/*17 genotype, both IM and EM phenotype were accepted in the presence of such 
diplotype. Underestimation of CYP2C19 phenotype occurred when the CYP2C19 activity-
based phenotypic category was higher than the corresponding genotype-based predicted 
phenotypic category. Conversely, overestimation was established when the CYP2C19 
activity-based phenotypic category was lower than the corresponding genotype-based 
predicted phenotypic category. The nonparametric Mann–Whitney test was performed for the 
comparison of mRNA expression levels between diplotype groups. 
 
Results 
Hepatic CYP2C19 activities 
CYP2C19 metabolic activities were measured using microsomes from 114 human liver 
tissues and (S)-mephenytoin as probe substrate [24]. Formation of 4’-hydroxymephenytoin by 
CYP2C19 was quantified based on “per mg microsomal protein and per minute”. Inter-
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individual variations of mephenytoin 4’-hydroxylase activities ranged from non-detectable to 
rather high values, and showed skewed distribution (Figure 1). The cut-off values (CI=95%) 
between categories of PMs, IMs, EMs and UMs were 8, 23 and 75 pmol/(mg*min), 
respectively. CYP2C19 activities were not affected by demographics, respecting donors’ age 
and sex; furthermore, we found no associations between causes of deaths and metabolic 
activities (data not shown). In the anamnesis of 7 donors, chronic alcohol consumption was 
reported, one donor was chronically treated with CYP2C19 substrate/inhibitor (ranitidine, 
carbamazepine), and 9 of the 114 donors were treated with amoxicillin-clavulanic acid. 
Diseases with inflammatory processes, such as epilepsy, rheumatoid arthritis and 
gastrointestinal perforation were diagnosed at 9 individuals. 
CYP2C19 allele frequencies 
The donors were genotyped for CYP2C19 allele variants most frequently occurring in 
Caucasian populations. CYP2C19*2 (19154G>A), CYP2C19*3 (17948G>A), CYP2C19*4 
(1A>G) and CYP2C19*17 (−806C>T) alleles were identified, all of which have functional 
impact on CYP2C19 enzyme activity. Wild-type allele was assessed when none of these 
mutations was detected. Allele frequencies of the 114 Hungarian organ donors were compared 
to those of other Caucasian populations (Table 3). The most frequent loss-of-function allele 
was CYP2C19*2 (allele frequency: 18.4%), which is in accordance with the literature data, 
whereas none of the donors carried the CYP2C19*3 and CYP2C19*4 variants. The prevalence 
of the CYP2C19*17 allele was modestly higher (26.3%) as compared with Caucasians. 
Homozygous loss-of-function (CYP2C19*2/*2) and homozygous gain-of-function 
(CYP2C19*17/*17) diplotypes occurred only at one and eight individuals, respectively, 
whereas 12 of the donors carried the ambiguously classifiable CYP2C19*2/*17 genotype. In 
accordance with previous observations [25], namely that the 19154G>A (CYP2C19*2) and 
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the -806C>T (CYP2C19*17) SNPs are in complete linkage disequilibrium, none of the donors 
in the study population carried these two mutations on the same haplotype. 
Association between CYP2C19 genotype and CYP2C19 enzyme activity 
Human organ donors were categorized as poor, intermediate, extensive and ultra-rapid 
metabolizers based on their corresponding CYP2C19 genotypes, and the genotype-based 
predicted phenotype was compared to the CYP2C19 activity-based phenotype (Figure 2). 
Altogether, one individual with two loss-of-function alleles (CYP2C19*2/*2) displayed low 
metabolic activity [7.6 pmol/(mg*min)] and accordingly PM phenotype. Mephenytoin 4’-
hydroxylase activities of the donors carrying one wild-type and one loss-of-function alleles 
varied between wide ranges [2-110 pmol/(mg*min)]; less than half of the donors (13/27) 
showed the predicted IM phenotype, a few of them (4/27) were PMs. Furthermore, 10 
heterozygous donors exhibited higher CYP2C19 activity than it could be predicted from their 
genotypes. 36 of the 114 donors carried homozygous wild genotype; however, only 14 
showed extensive metabolism; 11 and 7 of them were IMs and PMs, respectively. Four 
donors, despite their homozygous wild genotypes, showed rather high mephenytoin 
4’-hydroxylase activity, and therefore were categorized as phenotypic UMs. Almost all of the 
donors (10/12) with CYP2C19*2/*17 genotype were phenotypic IMs and EMs, except for two 
donors, one with slightly higher and one with lower activity, respectively. Donors with 
CYP2C19*1/*17 and CYP2C19*17/*17 genotypes are generally considered to be UMs. In our 
study, mephenytoin 4’-hydroxylase activity of the CYP2C19*17 carriers (both homozygous 
and heterozygous) showed enormous differences, and only a small proportion of the donors 
(8/38) exhibited ultra-rapid metabolism. Although CYP2C19 activities of the donors with 
CYP2C19*1/*17 genotype showed no difference [37.17±31.12 pmol/(mg*min) vs 
42.20±62.41 pmol/(mg*min), P=0.4209], the donors with CYP2C19*17/*17 genotype 
exhibited modestly, but not significantly higher mean activity value when compared to the 
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donors with homozygous wild genotype [81.77±71.48 pmol/(mg*min) vs 42.20±62.41 
pmol/(mg*min), P=0.0697]. 
Associations between CYP2C19 mRNA levels and CYP2C19*17 allele 
Mutation in the promoter region of CYP2C19*17 allele has been reported to increase the 
expression of CYP2C19 gene [5, 19]; therefore, the relative CYP2C19 mRNA levels in 
human liver tissues were investigated as the function of CYP2C19 genotype. No significant 
difference was found between CYP2C19 expression levels of each genotype group (Figure 
3/A.). Non-genetic factors (e.g. co-medication, nutrition, disease) have been demonstrated to 
substantially modify CYP2C19 expression and activity due to phenoconversion [26]; 
therefore, those individuals whose anamnesis contained CYP2C19 substrate/inhibitor therapy, 
amoxicillin-clavulanic acid therapy, chronic alcohol consumption or inflammatory processes, 
were excluded from the comparison analysis (Figure 3/B). Although no difference was 
observed in CYP2C19 expression between the donors with CYP2C19*1/*17, CYP2C19*1/*2, 
CYP2C19*2/*17 genotypes and the donors with CYP2C19*1/*1 genotype, CYP2C19*17/*17 
homozygous subjects showed significantly higher mRNA levels compared to the individuals 
with homozygous wild genotype (P=0.0227). 
Discussion 
The aim of this work was to elucidate the role of CYP2C19 genetic polymorphisms in 
CYP2C19 phenotypic appearance. In the present study, human liver microsomes isolated 
from Hungarian organ donors were characterized using mephenytoin 4’-hydroxylase activity 
as phenotyping assay and using CYP2C19 SNP genotyping platform for the allelic variants 
occurring most frequently in the Caucasian populations. CYP2C19 allele frequencies of 114 
Hungarian donors were consistent with previously described frequencies of Caucasian 
populations [8], and were also consistent with a pilot study on a Hungarian cohort published 
by Rideg et al. [27]. In the latter study by Rideg et al., the prevalence of the CYP2C19*2 
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variant was nearly identical compared to our results (16.5% vs 18.4%); however, detection of 
the CYP2C19*17 variant was not included in the trial. In our study population, functional 
defect of CYP2C19 gene was attributed solely to the presence of the CYP2C19*2 variant, 
since neither the CYP2C19*3 nor the CYP2C19*4 alleles occurred. The prevalence of the 
gain-of-function CYP2C19*17 allele was slightly higher compared to Caucasians (26.3% vs 
20-22%); however, the difference was not significant, owing to the relatively low number of 
the cohort. 
Up to now, clinical significance of the CYP2C19*2/*2 genotype in the metabolism of 
CYP2C19 substrates, such as clopidogrel, diazepam, omeprazole, proguanil, was 
unequivocally demonstrated by a number of in vivo trials [3, 21]. Since only one donor carried 
CYP2C19*2/*2 genotype in the current cohort, although this donor showed low mephenytoin 
4’-hydroxylase activity and was categorized as PM, the genotype group was inappropriate to 
compare with other diplotypes. The phenotype of the individuals with one loss-of-function 
and one wild-type alleles proved to be poorly predictable (13/27). Nine donors showed 
extensive and one donor displayed ultra-rapid metabolism, despite the lack of the -806C>T 
SNP in the promoter region of the gene or of medication of any pharmaceutics with CYP2C19 
inducing capabilities that potentially could increase the transcription of CYP2C19 gene via 
activating CAR/PXR or GR nuclear receptors. Four of the 36 donors with homozygous wild 
genotype were categorized as UMs based on their mephenytoin 4’-hydroxylase activity; 
however, individuals with wild diplotype are generally expected to be EMs. Underestimation 
of individuals’ phenotype could be explained by medication which is accountable for the 
activation of nuclear receptors (CAR/PXR or GR) and, hereby, for increased CYP2C19 
transcription [10], and was not listed in the clinical history of the donors. 
The phenotype of 53 of the 114 individuals was overestimated based on their 
corresponding genotype, 16 of them exhibited very low CYP2C19 metabolic activity and 
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were categorized as phenotypic PMs similarly to the donor carrying two loss-of-function 
alleles. This observation is in agreement with previous population studies, which 
demonstrated that the prevalence of phenotypic PM status exceeds the prevalence of 
genotypic PMs (data reviewed by Fricke-Galindo et al. [7]). Since a number of in vivo trials 
showed that PMs are endangered during CYP2C19 substrate drug therapy (e.g. clopidogrel, 
omeprazole, citalopram) [4, 11-15], it is essential to identify potential factors that could be 
responsible for the phenotype-genotype discrepancies, and could evoke phenoconversion and 
phenotypic poor metabolism despite the presence of one or two functional CYP2C19 alleles. 
In the present study, non-genetic factors, which are assuredly able to modify CYP2C19 
activity or liver metabolic function, were considered in the phenotype prediction. 
Co-administration of CYP2C19 substrates or inhibitors could lead to a decrease in metabolic 
capacity of CYP2C19 enzyme and to phenotypic poor metabolism, hence it could be the 
source of various drug-drug interactions [28, 29]. In the study population, one individual with 
homozygous wild genotype showed lower mephenytoin 4’-hydroxylase activity and was 
categorized as phenotypic IM. Regarding clinical data, this individual was on chronic 
ranitidine and carbamazepine therapy. Ranitidine is an H2-receptor antagonist, and is widely 
used to treat duodenal and stomach ulcers. Demethylation of ranitidine is principally catalysed 
by CYP2C19, CYP1A2 and CYP2D6 [30]. Although carbamazepine, an anti-epileptic agent, 
is a well-established inducer of various CYPs via CAR and PXR regulatory pathways [31], it 
has been shown that carbamazepine and its metabolites have the potential to inhibit the 
metabolism of CYP2C19 substrates [32]. Although both carbamazepine and ranitidine are 
competitive inhibitors and do not bind CYP2C19 enzyme covalently, phenotypic intermediate 
metabolism of the individual with homozygous wild-type alleles might be evolved due to the 
moderate phenoconversion caused by the supposed presence of the CYP2C19 substrate 
ranitidine and the CYP2C19 inhibitor carbamazepine and their metabolites in the 
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surroundings of CYP2C19 enzyme. Chronic alcohol consumption and amoxicillin-clavulanic 
acid treatment could also be responsible for phenotype conversion. Amoxicillin is an 
antibiotic drug applied in combination with clavulanic acid for treatment of various bacterial 
infections. Hepatotoxic effect of both amoxicillin-clavulanic acid and alcohol is well-
described [33]; however, their impact on CYP2C19 activity is hardly investigated. Our results 
suggested that amoxicillin-clavulanic acid treatment and chronic alcohol consumption are 
likely to have an aspecific effect and might contribute to the reduction of CYP2C19 activity, 
leading to discrepancies in the genotype-based phenotype prediction. Sixteen donors under 
chronic alcohol consumption or amoxicillin-clavulanic acid treatment exhibited lower 
CYP2C19 metabolic activity than it was predicted from their genotype data; moreover, 7 of 
them were PMs in spite of the presence of one or two either wild-type or gain-of-function 
CYP2C19*17 alleles. Ultimately, chronic diseases with inflammatory processes were also 
considered in the phenotype prediction. Inflammation-induced liver dysfunction is also a 
potential candidate that could have crucial role in phenoconversion. A number of trials 
investigated the alterations of CYP expression or metabolic capacities in different 
pathological conditions, indicating substantial reduction of CYP2C activities in patients with 
advanced cancer [34], congestive heart failure [35], epilepsy [36] as well as with liver disease 
[28, 37]. In pathological conditions, down-regulation of CYP2C19 gene expression was 
supposedly evoked by inflammatory cytokines; however, the regulatory mechanism is still 
unclear [26, 35, 38]. Diseases with inflammatory processes (epilepsy, rheumatoid arthritis and 
gastrointestinal perforation) were diagnosed at 9 individuals in our study population, all of 
them showed lower CYP2C19 activity than it was expected from their genotype data, and 2 of 
the 9 donors were categorized as phenotypic PMs. In the anamnesis of 27 donors, we were 
unable to explain the overestimated phenotype with any factors, including genetic and non-
genetic factors. Morbid obesity leading to inflammatory processes and lipid accumulation in 
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hepatocytes can be considered to be risk factors that can modify CYP2C19 expression and 
enzyme activity; however, histopathological evaluation of the liver tissues did not indicate 
steatotic status except for those with excessive alcohol intake. Supposedly, other factors not 
listed in the clinical history of the donors might affect the phenotypic appearance. Our results 
are in accordance with a recently published research using human liver microsomes and S-
mephenytoin as probe substrate [18]. Shirashaka et al. established that CYP2C19 genotype 
only partially contributed to the variability of CYP2C19 enzyme activity and expression. 
Furthermore, no association with clinical or demographic data was found; however, clinical 
information, such as drug treatment or disease, was not available at appreciable number of the 
donors [18]. Similar results were published by Gao et al., who concluded that the genotype 
and protein content of some CYPs had only limited effects on phenotypic appearance, which 
implied other important factors influencing inter-individual variations [16]. A potential source 
of inconsistencies can be the overlapping CYP2C19 metabolizer categories. There is a wide 
range of metabolic activity assigned to be extensive metabolizers, and still seems to overlap 
with the activities of intermediate metabolizers increasing the number of genotype-phenotype 
discrepancies. 
Effect of the CYP2C19*17 allele on gene expression was evaluated by analysing the 
association between CYP2C19 mRNA levels and CYP2C19 genotype data. We found no 
significant difference between the CYP2C19 mRNA levels of each genotype group; however, 
after excluding individuals with co-medication, chronic alcohol consumption, amoxicillin-
clavulanic acid treatment and inflammation-induced liver dysfunction, as potential factors 
evoking phenoconversion and discrepancies in genotype-based prediction, donors with 
CYP2C19*17/*17 diplotype showed significantly higher relative CYP2C19 expression 
compared to homozygous wild-type individuals. This finding is partially concordant with the 
results published by Sanford et al., who demonstrated that not only the donors with 
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CYP2C19*17/*17, but the subjects with CYP2C19*1/*17 diplotype showed significantly 
higher mRNA levels compared to donors with homozygous wild-type diplotype; however, 
these differences were not reflected by CYP2C19 enzyme activities [19]. 
In conclusion, CYP2C19 genotype is not the only determinant factor in CYP2C19 
metabolizer status, but co-medication with CYP2C19 substrate or inhibitor, diseases with 
inflammatory processes and aspecific factors, such as chronic alcohol consumption and 
amoxicillin-clavulanic acid therapy (or any drug therapy resulting in liver injury) might have 
the potential to modify CYP2C19 metabolic activity leading to genotype-phenotype 
mismatches. Furthermore, CYP2C19*17/*17 genotype determines the potential for increased 
gene expression and for ultra-rapid metabolism; however, phenotypic appearance seems to 
strongly depend on several non-genetic factors that may modify CYP2C19 metabolic 
capacity. 
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Figure legends 
Figure 1. Frequency distribution of hepatic mephenytoin 4’-hydroxylase activity 
selective for CYP2C19 in human organ donors (n=114) 
Figure 2. Hepatic CYP2C19 activity (mephenytoin 4’-hydroxylation) in subjects 
carrying various CYP2C19 genotypes 
 acceptable prediction from genotype,  underestimated phenotype 
from genotype,  overestimated phenotype from genotype, ○ chronic 
alcohol consumption,  liver dysfunction caused by disease,  
subjects under CYP2C19 substrate/inhibitor drug therapy,  subjects 
under amoxicillin-clavulanic acid therapy 
Figure 3. Association between CYP2C19 genotype and mRNA expression 
Data represents the relative mRNA expression values of 56 donors (A) 
and expression values of the donors after exclusion of individuals with 
potential phenotype-modifying non-genetic factors (chronic alcohol 
consumption, amoxicillin-clavulanic acid therapy, CYP2C19 
substrate/inhibitor therapy, disease with inflammation processes) (B). 
Data are presented as a box plot and whisker plot (box shows median 
with the 25th and 75th percentiles), and minimum and maximum values 
are shown by whiskers. Outliers that do not fall within the bounds of 
the plot are indicated with ○. 
Nonparametric Mann-Witney test was performed for the comparison of 
expression levels between the diplotype groups. *P<0.05 value was 
considered to be statistically significant. 
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Table 1 Demographic data of the human organ donors 
 Demographic data   
 
Donor number  
 
114 
Age (year)  median (min; max) 45 (13; 74) 
Gender  Male/female 60/52 
Cause of death    
 
 
Cerebral hemorrhage/ 
hematoma 
 61 
  Subarachnoid hemorrhage 30 
  Subdural hemorrhage 5 
  Epidural hematoma 1 
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  Intraventricular hemorrhage 5 
  Ruptured cerebral aneurysm 2 
  Unknown 18 
 
Stroke 
 
7 
  Ischemic stroke 6 
  Hemorrhagic stroke 1 
 
Tumour 
 
11 
 
Accident 
 
28 
  Car/motor/bike accident 5 
  
Seizure induced cerebral 
injury 
1 
  Suicide 4 
  Asphyxia 1 
  Unknown cerebral injury 17 
 
Unknown 
 
7 
Anamnesis  
  
 
 Alcohol consumption 7 
 
 
Medication with CYP2C19 
substrate/inhibitor 
1 
   
Medication with agent which 
cause potential liver 
dysfunction 
9 
  
Inflammation-induced liver 
dysfunction 
7 
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Table 2 Sequences of PCR primers and probes for CYP2C19 genotyping and mRNA quantitation 
FAM, CalRed610, HEX, fluorescent labelling; BHQ, black hole quencher 
 
Primer Sequence Probe Sequence 
SNP genotyping     
CYP2C19*2 Forward 5'-CTTAGATATGCAATAATTTTCCCAC-3' Wild FAM-TGATTATTTCCCGGGAACCCATAAC-BHQ1 
 
Reverse 5'-GAAGCAATCAATAAAGTCCCGA-3' Mutant CalRed610-TGATTATTTCCCAGGAACCCATAAC-BHQ2 
CYP2C19*3 Forward 5'-AGATCAGCAATTTCTTAACTTGATG-3' Wild FAM-ACCCCCTGGATCCAGG-BHQ1 
 
Reverse 5'-TGTACTTCAGGGCTTGGTC-3' Mutant CalRed610-ACCCCCTGAATCCAGG-BHQ2 
CYP2C19*4 Forward 5'-CAAAGAGGCACACACACTTA-3' Wild FAM-CAAGAGGAGAAGGCTTCAATGGAT-BHQ1 
 
Reverse 5'-CCAGATTGAAAGGAGAAGCA-3' Mutant HEX-CAAGAGGAGAAGGCTTCAGTGGAT-BHQ1 
CYP2C19*17 Forward 5'-ATGAACAGGATGAATGTGGTAT-3' Wild FAM-TCTGTTCTCAAAGCATCTCTGATGT-BHQ1 
 
Reverse 5'-TCTTCTGATGCCCATCGT-3'  Mutant HEX-TCTGTTCTCAAAGTATCTCTGATGT-BHQ1 
mRNA quantitation     
CYP2C19 Forward 5’-TGAAGGTGGAAATTTTAAGAAAAGTAA-3’ Probe FAM-5’-CAGCAGGA-3’-BHQ1 
 Reverse 5’-CCCTCTCCCACACAAATCC-3’   
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Table 3 Frequency of CYP2C19 alleles in the study population (n=114) and in Caucasians 
CYP2C19 allele 
Allele frequency (%) 
Subjects Caucasians[7, 8] 
*2 18.4 12-18 
*3 0 <1 
*4 0 <1 
*17 26.3 20-22 
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